Stockscreener 앱 받기
37.64
3.04%
1.11
시간 외 거래:
37.79
0.15
+0.40%
Sionna Therapeutics Inc 주식(SION)의 최신 뉴스
SION: NBD1 stabilizer programs target major CF mutations, with pivotal data expected mid-2026 - TradingView
What’s the MACD signal for Sionna Therapeutics Inc.July 2025 Outlook & Risk Adjusted Buy/Sell Alerts - mfd.ru
Volume Recap: Should you avoid Sionna Therapeutics Inc stock right nowEarnings Miss & Growth-Oriented Investment Plans - baoquankhu1.vn
Orbimed Advisors Llc Sells 29,063 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - Defense World
Sionna Therapeutics (NASDAQ:SION) Shares Down 14.6% on Insider Selling - Defense World
Sionna Therapeutics (NASDAQ:SION) Trading Down 14.6% Following Insider Selling - MarketBeat
OrbiMed Advisors LLC sells Sionna Therapeutics (SION) stock worth $1.37m - Investing.com
OrbiMed Advisors LLC sells Sionna Therapeutics (SION) stock worth $1.37m By Investing.com - Investing.com South Africa
Thompson Peter a. sells Sionna Therapeutics (SION) shares for $1.37m By Investing.com - Investing.com South Africa
Thompson Peter a. sells Sionna Therapeutics (SION) shares for $1.37m - Investing.com India
Sionna Therapeutics (NASDAQ:SION) Director Orbimed Advisors Llc Sells 29,063 Shares - MarketBeat
Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - markets.businessinsider.com
Sionna Therapeutics (NASDAQ:SION) Director Sells $84,237.30 in Stock - MarketBeat
Support Test: Whats the outlook for Sionna Therapeutics Incs sectorTrade Risk Summary & Smart Allocation Stock Reports - baoquankhu1.vn
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
TPG GP A, LLC Reduces Stake in Sionna Therapeutics Inc - GuruFocus
Sionna Therapeutics, Inc. (SION) Stock Analysis: Biotech’s Promising Prospects with 5.7% Upside Potential - DirectorsTalk Interviews
Sionna Therapeutics (SION) 10% owners sell $10 million in stock By Investing.com - Investing.com South Africa
Major Stake Unloaded in Sionna Therapeutics Sparks Fresh Market Buzz - TipRanks
Tpg Gp A, Llc Sells 250,000 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - MarketBeat
Sionna Therapeutics (SION) 10% owners sell $10 million in stock - Investing.com
Sionna Therapeutics (NASDAQ:SION) Shares Gap DownHere's Why - MarketBeat
Sionna Therapeutics, Inc. (SION) Stock Analysis: Exploring a 7.39% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Aug Sentiment: Should you avoid Sionna Therapeutics Inc stock right now - baoquankhu1.vn
Sionna Therapeutics Chief Legal Officer Caps Off Strong 2025 with Sale of Over 10,000 Shares - AOL.com
Sionna Therapeutics (NASDAQ:SION) Stock Price Up 8.1%Here's Why - MarketBeat
Multiple Shots on Goal in Cystic Fibrosis: Sionna’s NBD1-Targeted Pipeline and 2026 Clinical Readouts Drive Buy Thesis and $58 DCF-Based Target - TipRanks
BTIG Research Reiterates Buy Rating for Sionna Therapeutics (NASDAQ:SION) - MarketBeat
SION: Advancing NBD1 stabilizers to transform CF care, with key data expected mid-2026 - TradingView
SION: First-in-class NBD1 stabilizers target full CFTR correction, with pivotal data expected mid-2026 - TradingView — Track All Markets
Sionna Therapeutics (NASDAQ:SION) Stock Price Down 10.1%Here's What Happened - MarketBeat
Assessing Sionna Therapeutics (SION) Valuation After Recent Share Price Swings And Premium P/B Multiple - Yahoo Finance
Sionna Therapeutics Advances Cystic Fibrosis Treatment with New Study - MSN
Sionna Therapeutics, Inc. (SION) Stock Analysis: A 27.73% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Assessing Sionna Therapeutics (SION) Valuation After A Sharp Share Price Move And Elevated Price To Book Ratio - Sahm
Market Recap: How Sionna Therapeutics Inc. stock compares to industry benchmarks2025 Sector Review & Trade Opportunity Analysis - Улправда
Is Sionna Therapeutics Inc. stock positioned for long term growthPortfolio Value Summary & Smart Money Movement Tracker - Улправда
Sionna Therapeutics (NASDAQ:SION) Trading Up 7.7%Here's Why - MarketBeat
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Sionna Therapeutics (NASDAQ:SION) Shares Down 7.5%What's Next? - MarketBeat
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Orbimed Advisors LLC Reduces Stake in Sionna Therapeutics Inc - GuruFocus
Raymond James raises Sionna Therapeutics stock price target on CF drug potential - Investing.com Canada
Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million - AOL.com
A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million - The Motley Fool
Sionna Therapeutics Insider Sold Shares Worth $1,486,010, According to a Recent SEC Filing - marketscreener.com
1.24%
0.19%
자본화:
|
볼륨(24시간):